MDXG Mimedx Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDXG

Price (delayed)

$7.37

Market cap

$1.09B

P/E Ratio

14.17

Dividend/share

N/A

EPS

$0.52

Enterprise value

$1.06B

MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. ...

Highlights
The debt has plunged by 60% from the previous quarter and by 60% YoY
Mimedx Group's EPS has increased by 30% QoQ
The quick ratio has decreased by 15% QoQ and by 3.5% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.mimedx.com
Peers: MDT TFX ATEC STE

Key stats

What are the main financial stats of MDXG
Market
Shares outstanding
147.6M
Market cap
$1.09B
Enterprise value
$1.06B
Valuations
Price to earnings (P/E)
14.17
Price to book (P/B)
6.95
Price to sales (P/S)
3.23
EV/EBIT
22.9
EV/EBITDA
20.86
EV/Sales
3.17
Earnings
Revenue
$334.51M
EBIT
$46.24M
EBITDA
$50.76M
Free cash flow
$34.3M
Per share
EPS
$0.52
Free cash flow per share
$0.23
Book value per share
$1.06
Revenue per share
$2.28
TBVPS
$1.3
Balance sheet
Total assets
$221.68M
Total liabilities
$65.95M
Debt
$19.45M
Equity
$155.73M
Working capital
$96.63M
Liquidity
Debt to equity
0.12
Current ratio
3.29
Quick ratio
2.5
Net debt/EBITDA
-0.57
Margins
EBITDA margin
15.2%
Gross margin
83.5%
Net margin
22.2%
Operating margin
16%
Efficiency
Return on assets
35.9%
Return on equity
103.3%
Return on invested capital
43.1%
Return on capital employed
25.8%
Return on sales
13.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDXG stock price

How has the Mimedx Group stock price performed over time
Intraday
-1.73%
1 week
17.54%
1 month
5.14%
1 year
38.79%
YTD
-15.96%
QTD
-4.29%

Financial performance

How have Mimedx Group's revenue and profit performed over time
Revenue
$334.51M
Gross profit
$279.31M
Operating income
$53.57M
Net income
$74.16M
Gross margin
83.5%
Net margin
22.2%
The operating income rose by 44% QoQ
The operating margin has grown by 39% from the previous quarter
MDXG's net income is up by 27% QoQ
The net margin has grown by 23% from the previous quarter

Growth

What is Mimedx Group's growth rate over time

Valuation

What is Mimedx Group stock price valuation
P/E
14.17
P/B
6.95
P/S
3.23
EV/EBIT
22.9
EV/EBITDA
20.86
EV/Sales
3.17
Mimedx Group's EPS has increased by 30% QoQ
Mimedx Group's equity has increased by 9% QoQ
The P/S is 29% higher than the 5-year quarterly average of 2.5 and 8% higher than the last 4 quarters average of 3.0
MDXG's revenue is up by 19% YoY and by 4.1% from the previous quarter

Efficiency

How efficient is Mimedx Group business performance
Mimedx Group's return on sales has surged by 59% QoQ
MDXG's return on invested capital has surged by 54% since the previous quarter
Mimedx Group's return on equity has decreased by 50% QoQ
MDXG's ROA is up by 19% QoQ

Dividends

What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDXG.

Financial health

How did Mimedx Group financials performed over time
The total assets has grown by 32% YoY but it has contracted by 7% from the previous quarter
The total liabilities has contracted by 32% from the previous quarter and by 30% YoY
The debt is 88% less than the equity
MDXG's debt to equity has soared by 104% year-on-year but it has dropped by 65% since the previous quarter
The debt has plunged by 60% from the previous quarter and by 60% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.